Search Results 71-80 of 16666 for ������������KA���:ZA31���24������ ���������������������������������

  1. Surgical Drain Fluid for Detection of Molecular Residual Disease (MRD) in Bladder, Renal and Urothelial Cancers - Mayo Clinic

    Rochester, Minnesota: 24-013778. Sponsor Protocol Number: 24-013. About this study. The purpose of this study is to investigate if DNA cancer-associated ...

  2. Hyperparathyroidism - Diagnosis & treatment - Mayo Clinic

    Testing a sample of urine collected over 24 hours can show how well the kidneys work and how much calcium is in the urine. If you have hyperparathyroidism ...

  3. A Study of Patient Centered Approaches to Gene Editing - Mayo Clinic

    Overview. Tab Title Description. Study IDs. Study IDs. Site IRB. Rochester, Minnesota: 24-005545; Jacksonville, Florida: 24-005545. About this study. The ...

  4. GS-4997 in Adults With Pulmonary Arterial Hypertension - Mayo Clinic

    The study will consist of a 24-week placebo-controlled treatment period and a long-term GS-4997 treatment period. Participants completing the 24-week ...

  5. sexually transmitted infections Archives - Mayo Clinic News Network

    ... 24, gay and bisexual men, and pregnant women. "We know that young people between the age of 15 and 24 are about a quarter of the sexually active people in ...

  6. Clinical Trials

    Blood is inherently well suited for detection of cancer biomarkers as it contains circulating tumor cells and tumor cell-free DNA (cfDNA) that have been “shed” ...

  7. Health Topics - Mayo Clinic News Network

    January 24, 2025. Featured News. Mayo Clinic Q and A: Living kidney donation can start a chain reaction. Susan Barber Lindquist. January 24, 2025. Health ...

  8. Mayo Clinic

    Overview. Tab Title Description. Study IDs. Study IDs. Site IRB. Rochester, Minnesota: 24-012753; Jacksonville, Florida: 24-012753; Scottsdale/Phoenix, Arizona: ...

  9. Clinical trials - Oncology (Medical)

    The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 24 months of HLA-A LOH status; Percentage of screened ...

  10. Belzutifan with Von Hippel-Lindau (VHL) - Mayo Clinic

    Rochester, Minnesota: 24-007537; Scottsdale/Phoenix, Arizona: 24-007537. Sponsor Protocol Number: 6482-026. About this study. The purpose of this study is to ...